Literature DB >> 15968081

2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.

Morris H Baslow1, Victor V Dyakin, Karen L Nowak, Basalingappa L Hungund, David N Guilfoyle.   

Abstract

N-acetylaspartylglutamate (NAAG), a dipeptide derivative of N-acetylaspartate (NAA) and glutamate (Glu), is present in neurons. Upon neurostimulation, NAAG is exported to astrocytes where it activates a specific metabotropic Glu surface receptor (mGluR3), and is then hydrolyzed by an astrocyte-specific enzyme, NAAG peptidase, liberating Glu, which can then be taken up by the astrocyte. NAAG is a selective mGluR3 agonist, one of several mGluRs that, when activated, triggers Ca2+ waves that spread to astrocytic endfeet in contact with the vascular system, where a secondary release of vasoactive agents induces a focal hyperemic response providing increased oxygen and nutrient availability to the stimulated neurons. Changes in blood oxygen levels can be assessed in vivo using a blood oxygenation level-dependent (BOLD) magnetic resonance imaging technique that reflects a paramagnetic effect of deoxyhemoglobin. In this study we used the competitive NAAG peptidase inhibitor 2-(phosphonomethyl) pentanedioic acid (2-PMPA) as a probe to interrupt the NAAG-mGluR3- Glu-astrocyte Ca2+ activation sequence. Using this probe, we investigated the relationship between release of the endogenous neuropeptide NAAG and brain blood oxygenation levels, as measured by changes in BOLD signals. In an anesthetized mouse, using an overtly nontoxic dose of 2-PMPA of 250 mg/kg i.p., there was an initial global BOLD signal increase of about 3% above control, lasting about 4 min, followed by a decrease from control of about 4%, sustained over a 32.5-min period of the drug test procedure. Similar changes, but of reduced magnitude and duration, were observed at a dose of 167 mg/kg. The 2-PMPA-induced decreases in BOLD signals appear to indicate that blood deoxyhemoglobin is elevated when endogenous NAAG cannot be hydrolyzed, thus linking the efflux of NAAG from neurons and its hydrolysis by astrocytes to hyperemic oxygenation responses in brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968081     DOI: 10.1385/JMN:26:1:001

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  34 in total

Review 1.  Spatial localization and resolution of BOLD fMRI.

Authors:  E Zarahn
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

2.  DISTRIBUTION OF N-ACETYL-ASPARTIC AND N-ACETYL-ASPARTYL-GLUTAMIC ACIDS IN NERVOUS TISSUE.

Authors:  A CURATOLO; P D ARCANGELO; A LINO; A BRANCATI
Journal:  J Neurochem       Date:  1965-04       Impact factor: 5.372

3.  CBF changes during brain activation: fMRI vs. PET.

Authors:  Ching-Mei Feng; Shalini Narayana; Jack L Lancaster; Paul A Jerabek; Thomas L Arnow; Fang Zhu; Li Hai Tan; Peter T Fox; Jia-Hong Gao
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

4.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.

Authors:  B S Slusher; J J Vornov; A G Thomas; P D Hurn; I Harukuni; A Bhardwaj; R J Traystman; M B Robinson; P Britton; X C Lu; F C Tortella; K M Wozniak; M Yudkoff; B M Potter; P F Jackson
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

5.  Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: implications for axon-glia signaling.

Authors:  A K Urazaev; J G Buttram; J P Deen; B S Gafurov; B S Slusher; R M Grossfeld; E M Lieberman
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 6.  Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling.

Authors:  M H Baslow
Journal:  J Neurochem       Date:  2000-08       Impact factor: 5.372

7.  Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys.

Authors:  Z Zhang; A H Andersen; M J Avison; G A Gerhardt; D M Gash
Journal:  Brain Res       Date:  2000-01-10       Impact factor: 3.252

8.  Labeling of N-acetylaspartate and N-acetylaspartylglutamate in rat neocortex, hippocampus and cerebellum from [1-13C]glucose.

Authors:  R L Tyson; G R Sutherland
Journal:  Neurosci Lett       Date:  1998-07-31       Impact factor: 3.046

9.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase.

Authors:  P F Jackson; D C Cole; B S Slusher; S L Stetz; L E Ross; B A Donzanti; D A Trainor
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

10.  Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation.

Authors:  Micaela Zonta; María Cecilia Angulo; Sara Gobbo; Bernhard Rosengarten; Konstantin-A Hossmann; Tullio Pozzan; Giorgio Carmignoto
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

View more
  14 in total

1.  Effects of lamotrigine on hippocampal activation in corticosteroid-treated patients.

Authors:  E Sherwood Brown; Liam Zaidel; Greg Allen; Roderick McColl; Miguel Vazquez; Wendy K Ringe
Journal:  J Affect Disord       Date:  2010-05-23       Impact factor: 4.839

2.  Stimulus-induced Rotary Saturation (SIRS): a potential method for the detection of neuronal currents with MRI.

Authors:  Thomas Witzel; Fa-Hsuan Lin; Bruce R Rosen; Lawrence L Wald
Journal:  Neuroimage       Date:  2008-05-20       Impact factor: 6.556

3.  MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-10-01       Impact factor: 5.067

4.  Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications.

Authors:  N Agarwal; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-29       Impact factor: 3.825

5.  Stimulation-induced transient changes in neuronal activity, blood flow and N-acetylaspartate content in rat prefrontal cortex: a chemogenetic fMRS-BOLD study.

Authors:  Morris H Baslow; Christopher K Cain; Robert Sears; Donald A Wilson; Alvin Bachman; Scott Gerum; David N Guilfoyle
Journal:  NMR Biomed       Date:  2016-10-03       Impact factor: 4.044

6.  Investigation of NAA and NAAG dynamics underlying visual stimulation using MEGA-PRESS in a functional MRS experiment.

Authors:  Ricardo C G Landim; Richard A E Edden; Bernd Foerster; Li Min Li; Roberto J M Covolan; Gabriela Castellano
Journal:  Magn Reson Imaging       Date:  2015-12-02       Impact factor: 2.546

7.  Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia.

Authors:  Subroto Ghose; Ronald Chin; Analysa Gallegos; Rosalinda Roberts; Joseph Coyle; Carol Tamminga
Journal:  Schizophr Res       Date:  2009-04-28       Impact factor: 4.939

8.  Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?

Authors:  Subroto Ghose; Kelly A Gleason; Bryan W Potts; Kelly Lewis-Amezcua; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2009-06-01       Impact factor: 18.112

Review 9.  The Impact of Neuroimmune Alterations in Autism Spectrum Disorder.

Authors:  Carmem Gottfried; Victorio Bambini-Junior; Fiona Francis; Rudimar Riesgo; Wilson Savino
Journal:  Front Psychiatry       Date:  2015-09-09       Impact factor: 4.157

10.  Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI.

Authors:  Anthony Bejjani; Joseph O'Neill; John A Kim; Andrew J Frew; Victor W Yee; Ronald Ly; Christina Kitchen; Noriko Salamon; James T McCracken; Arthur W Toga; Jeffry R Alger; Jennifer G Levitt
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.